Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025.
Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast.
The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.
In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.
Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplir™
Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+™ and Remplir™.
The first episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring CEO & MD, Paul Anderson.
As part of a special ‘Meet the Board’ video series launching in October 2024, we are pleased to bring you face to face with the team at the top. Tune in for inspiring insights into their vision for our Company.
Orthocell Chairman, John Van Der Wielen spoke with ausbiz host Nadine Blayney about the Company’s expansion into Canada with dental bone regeneration product, Striate+, and Orthocell’s strong outlook for revenue growth.
Following the Company’s announcement last week confirming the first sales of Striate+ in Canada, Orthocell’s Chairman John Van Der Wielen spoke with Proactive’s Tylah Tully about the Company’s swift transition from regulatory approval to sales in the Canadian market, and plans to expand into the Singapore and Brazil markets within the next six to 12 months.